This study evaluated the feasibility of the sFlt-1/PlGF biomarker ratio in predicting preeclampsia and adverse pregnancy outcomes, with the goal of preventive therapy with acetylsalicylic acid (150 mg daily), acetylsalicylic acid (75 mg/daily) and Clampsillin. Here, PGF is linked to preeclampsia.